Skip to content

Ananda Pharma PLC - Master Investor Conference Attendance


Announcement provided by

Ananda Pharma Plc · ANA

12/03/2025 07:00

Ananda Pharma PLC - Master Investor Conference Attendance
RNS Number : 2499A
Ananda Pharma PLC
12 March 2025
 

 

A logo with blue and green dots Description automatically generated

 12 March 2025

 

ANANDA PHARMA PLC

("Ananda" or the "Company")

 

Ananda to present at Master Investor Show in London

 

Ananda Pharma plc (AQSE: ANA), a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, is pleased to announce that its leadership team will be presenting the Ananda Pharma opportunity at the Master Investor Show in London at The Business Design Centre, 52 Upper Street, London N1 0QH, on Saturday, 29th March. Ananda will be present all day at booth M:35.

 

Jeremy Sturgess-Smith, Finance Director will be presenting on the Showcase stage at 10:25, the Company will also be exhibiting at Booth M:35 throughout the day and Melissa Sturgess, CEO will also be attending the event all day.

 

Melissa Sturgess, CEO, commented: "We are very much looking forward to participating in Master Investor again this year. It is a great opportunity to speak to existing and potential new shareholders about our drive to bring cannabis based, regulatory approved medicines to the market. We invite everyone to come and say hello at our Booth, number M:35."

 

To register for the Master Investor Show, please use the following link: https://masterinvestorshow-2025.reg.buzz/?exhibitor-inviter=848eac18-dfd9-11ef-99be-000000000000

 

About Ananda Pharma

 

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

 

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

 

-Ends-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For more information please contact:

ANANDA PHARMA PLC

 

 

Chief Executive Officer

Melissa Sturgess


Finance Director

Jeremy Sturgess-Smith

 

+44 (0)7463 686 497 jss@anandapharma.co.uk

 

SP ANGEL CORPORATE FINANCE LLP

 

 

Corporate Finance

Richard Morrison

Josh Ray

+44 (0)20 3470 0470

Corporate Broking

Abigail Wayne

Rob Rees

 


YELLOW JERSEY PR

 

 

Sarah Macleod

Charles Goodwin

Zara McKinlay

+44 (0)20 3004 9512

ananda@yellowjerseypr.com

 

 

 

https://investors.anandapharma.co.uk/link/mep3Xy

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFVRVRILLIE]]>

View more ...

ANA announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2025. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal